کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3466033 1596541 2015 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story
ترجمه فارسی عنوان
ریتوکسیامب در پورپورای ترومبوسیتوپنیک ترومبوتیک اتوایمیون: داستان موفقیت
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی پزشکی و دندانپزشکی (عمومی)
چکیده انگلیسی


• Rituximab is recommended in acquired TTP with a suboptimal response with standard management.
• Rituximab should be considered in patients with severe ADAMTS13 deficiency during TTP remission.
• Rituximab in acquired TTP is associated with acceptable side effects.

Despite a significant improvement of thrombotic thrombocytopenic purpura (TTP) prognosis since the use of plasma exchange, morbidity and mortality remained significant because of poor response to standard treatment or exacerbations and relapses. Rituximab, a chimeric monoclonal antibody directed against the B-lymphocyte CD20 antigen, has shown a particular interest in this indication. Recent studies also reported strong evidence for its efficiency in the prevention of relapses. This review addresses these recent progresses and still opened questions in this topic: should rituximab be proposed in all patients at the acute phase? Should all patients benefit from a preemptive treatment? Is the infectious risk acceptable in this context?

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Internal Medicine - Volume 26, Issue 9, November 2015, Pages 659–665
نویسندگان
, , , , ,